Pharsight

1. List of Acetadote drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445	CUMBERLAND PHARMS	Acetylcysteine composition and uses thereof	Aug, 2025 (2 years from now)
US8653061	CUMBERLAND PHARMS	Acetylcysteine composition and uses thereof	Aug, 2025 (2 years from now)
US8148356	CUMBERLAND PHARMS	Acetylcysteine composition and uses therefor	May, 2026 (3 years from now)
US9327028	CUMBERLAND PHARMS	Acetylcysteine compositions and methods of use thereof	Jul, 2031 (8 years from now)
US8722738	CUMBERLAND PHARMS	Acetycysteine compositions and methods of use thereof	Apr, 2032 (9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg/mL, 30 mL vials	04 Apr, 2012	3	07 Nov, 2012	21 May, 2026	Eligible

Strength	Dosage	Availability
6GM/30ML (200MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

2. List of Caldolor drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9114068	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US8735452	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9649284	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US8871810	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9295639	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9012508	CUMBERLAND PHARMS	Administration of intravenous ibuprofen	Sep, 2030 (7 years from now)
US9072661	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)
US9072710	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

3. List of Vibativ drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6635618	CUMBERLAND PHARMS	Glycopeptide phosphonate derivatives	Sep, 2023 (7 months from now)
US7531623	CUMBERLAND PHARMS	Hydrochloride salts of a glycopeptide phosphonate derivative	Jan, 2027 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858584	CUMBERLAND PHARMS	Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin	Aug, 2022 (5 months ago)